Xin Lang Cai Jing·2025-09-11 10:14Core Viewpoint - Rongchang Biopharmaceuticals has shown a significant increase in stock price, reflecting positive market sentiment and investor interest in its innovative biopharmaceutical products [1] Company Overview - Rongchang Biopharmaceuticals, established on July 4, 2008, and listed on March 31, 2022, is located in the Yantai Free Trade Zone, Shandong, China [1] - The company focuses on the development and commercialization of innovative biopharmaceuticals, particularly in the fields of antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies [1] - The main revenue sources for the company are product sales (99.46%), material sales (0.38%), and leasing services (0.16%) [1] Financial Performance - As of the report date, Rongchang Biopharmaceuticals' stock price is 108.37 CNY per share, with a trading volume of 1.022 billion CNY and a turnover rate of 6.32%, leading to a total market capitalization of 61.078 billion CNY [1] Fund Holdings - The Huatai-PB Fund holds a significant position in Rongchang Biopharmaceuticals, with its Huatai-PB SSE STAR Market Comprehensive ETF Linked A (023741) being the largest shareholder, owning 627 shares, which constitutes 0.02% of the fund's net value [2] - The fund has achieved a return of 27.55% since its inception on April 18, 2025 [2] Fund Manager Information - The fund manager of Huatai-PB SSE STAR Market Comprehensive ETF Linked A is Tan Hongxiang, who has been in the position for 4 years and 187 days, managing a total asset size of 27.342 billion CNY [3] - During his tenure, the best fund return was 78.18%, while the worst return was -37.2% [3]